Salarius Pharmaceuticals (Nasdaq:SLRX) - Cotización, noticias y análisis

Resumen de acción SLRX

Salarius Pharmaceuticals, Inc. es una empresa biotecnológica en fase clínica dedicada al desarrollo de tratamientos para cánceres con necesidades médicas no cubiertas.

Acerca de la empresa

Análisis fundamental de SLRX
Puntuación del snowflake
Valoración	2/6
Crecimiento futuro	0/6
Rendimiento pasado	0/6
Salud financiera	4/6
Dividendos	0/6

Recompensas

Análisis de riesgos

Los accionistas han sido diluidos sustancialmente en el último año

Se prevé que los beneficios disminuyan un promedio de 42.8% al año durante los próximos 3 años

No tiene una capitalización de mercado significativa ($2M)

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

+ 3 riesgos adicionales

Competidores de Salarius Pharmaceuticals, Inc.

Vaxxinity

OTCPK:VAXX

US$6.3m

Aptevo Therapeutics

NasdaqCM:APVO

US$2.3m

GlycoMimetics

NasdaqGM:GLYC

US$10.6m

Enzon Pharmaceuticals

OTCPK:ENZN

US$10.4m

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Salarius Pharmaceuticals
Precios históricos de las acciones
Precio actual de la acción	US$1.71
Máximo en las últimas 52 semanas	US$7.60
Mínimo de 52 semanas	US$1.35
Beta	0.96
1Cambio en 1 mes	-8.06%
Variación en 3 meses	-29.34%
Cambio de 1 año	-70.35%
3Variación en 3 años	-99.26%
Variación en 5 años	-99.84%
Variación desde la OPV	-99.93%

Noticias y actualizaciones recientes

Recent updates

Salarius pharmaceuticals announces 1-for-25 reverse stock split

Oct 14

Salarius adds 12% after updates on clinical programs and financials

Sep 13

Salarius Pharma adds two Mayo Clinic sites to phase 1/2 trial of Seclidemstat as treatment for cancers

Aug 22

Salarius Pharmaceuticals GAAP EPS of -$0.09 beats by $0.01

Aug 08

Salarius Pharmaceuticals and VolitionRx enter into R&D collaboration agreement

Aug 02

Salarius Pharma reports new seclidemstat results in Ewing sarcoma and other solid tumors at ASCO21

Jun 07

Salarius Pharmaceuticals (SLRX) Investor Presentation - Slideshow

May 27

Salarius Pharmaceuticals (NASDAQ:SLRX) Shareholders Have Enjoyed An Impressive 155% Share Price Gain

Feb 09

Rentabilidad de los accionistas

	SLRX	US Biotechs	Mercado US
7D	9.6%	-1.2%	1.6%
1Y	-70.4%	22.9%	30.6%

Rentabilidad vs. Industria: Los resultados de SLRX fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 12.6% el año pasado.

Rentabilidad vs. Mercado: SLRX obtuvo unos resultados inferiores a los del mercado US, que fueron del 22.3% el año pasado.

Volatilidad de los precios

Is SLRX's price volatile compared to industry and market?
SLRX volatility
SLRX Average Weekly Movement	38.1%
Biotechs Industry Average Movement	10.2%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.1%
10% least volatile stocks in US Market	3.1%

Precio estable de las acciones: El precio de las acciones de SLRX ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de SLRX ha aumentado de 14% a 21% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
n/a	2	David Arthur	www.salariuspharma.com

Salarius Pharmaceuticals, Inc. es una empresa biotecnológica en fase clínica centrada en el desarrollo de tratamientos para cánceres con necesidades médicas no cubiertas. Su principal candidato es Seclidemstat (SP-2577), un pequeño inhibidor molecular que se encuentra en ensayos clínicos de fase I/II para el tratamiento de tumores sólidos avanzados, así como del sarcoma de Ewing. La empresa también ofrece SP-3164, un pequeño degradador molecular de proteínas para el tratamiento de tumores hematológicos y sólidos.

Resumen de fundamentos de Salarius Pharmaceuticals, Inc.

¿Cómo se comparan los beneficios e ingresos de Salarius Pharmaceuticals con su capitalización de mercado?
Estadísticas fundamentales de SLRX
Capitalización bursátil	US$2.46m
Beneficios(TTM)	-US$6.46m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-0.4x

Ratio precio-beneficio (PE)

¿Está SLRX sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de SLRX
Ingresos	US$0
Coste de los ingresos	US$0
Beneficio bruto	US$0
Otros gastos	US$6.46m
Beneficios	-US$6.46m

Últimos beneficios comunicados

Jun 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-4.49
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado SLRX a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción SLRX

Recompensas

Análisis de riesgos

Competidores de Salarius Pharmaceuticals, Inc.

OTCPK:VAXX

US$6.3m

NasdaqCM:APVO

US$2.3m

NasdaqGM:GLYC

US$10.6m

OTCPK:ENZN

US$10.4m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with Mds and Cmml Presented At the 2024 European Hematology Association Annual Meeting

New major risk - Shareholder dilution

Nasdaq Grants an Additional 180-Day Grace Period to Salarius Pharmaceuticals to Regain Compliance

Salarius Pharmaceuticals, Inc. Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

Salarius Pharmaceuticals, Inc. Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Salarius Pharmaceuticals Receives Notice from Nasdaq Stock Market

Recent updates

Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with Mds and Cmml Presented At the 2024 European Hematology Association Annual Meeting

New major risk - Shareholder dilution

Nasdaq Grants an Additional 180-Day Grace Period to Salarius Pharmaceuticals to Regain Compliance

Salarius Pharmaceuticals, Inc. Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

Salarius Pharmaceuticals, Inc. Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Salarius Pharmaceuticals Receives Notice from Nasdaq Stock Market

Insufficient new directors

Salarius Pharmaceuticals, Inc. FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

Salarius Pharmaceuticals, Inc. announced that it has received $6.000001 million in funding

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

Salarius Pharmaceuticals Presents Sp-3164 Preclinical Data At the Inaugural Molecular Glue Drug Development Summit

Salarius Pharmaceuticals, Inc. to Present SP-3164 Targeted Protein Degrader Preclinical Data At the Inaugural Molecular Glue Drug Development Summit

Salarius Pharmaceuticals, Inc. Announces Investigators Present Clinical Data on Its Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals, Inc. Reports Impairment of Goodwill for the Three Months Ended September 30, 2022

Salarius Pharmaceuticals Presents Favorable Preclinical Data on Sp-3164 At the 5Th Annual Targeted Protein Degradation Conference

Salarius Pharmaceuticals, Inc. Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius pharmaceuticals announces 1-for-25 reverse stock split

Salarius adds 12% after updates on clinical programs and financials

Salarius Pharma adds two Mayo Clinic sites to phase 1/2 trial of Seclidemstat as treatment for cancers

Salarius Pharmaceuticals GAAP EPS of -$0.09 beats by $0.01

Salarius Pharmaceuticals, Inc. Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for Ongoing Trial of Seclidemstat as A Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals and VolitionRx enter into R&D collaboration agreement

Salarius Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 05, 2022

Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration

Salarius Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Salarius Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program

Salarius Pharmaceuticals, Inc. (NasdaqCM:SLRX) acquired certain assets of DeuteRx, including DRX-164 for approximately $220 million.

Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.069 loss per share (vs US$0.13 loss in 2Q 2020)

Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers

Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstat’S Safety, Dosing, and Drug Activity At American Society of Clinical Oncology (Asco) 2021 Annual Meeting

Salarius Pharma reports new seclidemstat results in Ewing sarcoma and other solid tumors at ASCO21

Salarius Pharmaceuticals (SLRX) Investor Presentation - Slideshow

Price target decreased to US$4.10

Salarius Pharmaceuticals, Inc. Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

First quarter 2021 earnings released: US$0.061 loss per share (vs US$0.22 loss in 1Q 2020)

Full year 2020 earnings released: US$0.50 loss per share (vs US$2.12 loss in FY 2019)

Salarius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $19.999999 million.

Salarius Pharmaceuticals, Inc. Initiates Expansion Stage of Phase 1/2 Clinical Trial of Seclidemstat in Patients with Ewing Sarcoma and Ewing-Related Sarcomas

Salarius Pharmaceuticals, Inc. Completes Dose-Escalation Stage of Phase 1/2 Clinical Trial in Relapsed and Refractory Ewing Sarcoma Patients, Initiates Expansion Stage in Ewing and Ewing-Related Sarcoma Patients

Salarius Pharmaceuticals (NASDAQ:SLRX) Shareholders Have Enjoyed An Impressive 155% Share Price Gain

New 90-day high: US$1.58

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

New 90-day high: US$1.35

Salarius Pharmaceuticals, Inc. Announces Developing Seclidemstat

Salarius Pharmaceuticals receives second installment of $1.7M in payments

Salarius Pharma raises $3.5M via warrant exercise

New 90-day high: US$1.08

Revenue beats expectations, earnings disappoint

Third quarter 2020 earnings released: US$0.096 loss per share

Salarius Pharmaceuticals EPS in-line, beats on revenue

New 90-day low: US$0.73

New 90-day low: US$0.80

New 90-day low - US$0.99

Earnings released

Salarius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $5.353451 million.